Recombinant PCSK9 (Lodelcizumab Biosimilar) antibody

Catalog No. ABIN7488018

The Mammalian Cells Monoclonal anti-PCSK9 (Lodelcizumab Biosimilar) antibody has been validated for ELISA. It is suitable to detect PCSK9 (Lodelcizumab Biosimilar) in samples from Human.

Quick Overview for Recombinant PCSK9 (Lodelcizumab Biosimilar) antibody (ABIN7488018)

Target: PCSK9 (Lodelcizumab Biosimilar)

Antibody Type: Recombinant Antibody

Reactivity: Human

Host: Mammalian Cells

Clonality: Monoclonal

Conjugate: This PCSK9 (Lodelcizumab Biosimilar) antibody is un-conjugated

Application: ELISA

Grade: Research Grade

Product Details anti-PCSK9 (Lodelcizumab Biosimilar) Antibody

Expression System: Mammalian cells

Purpose: Lodelcizumab Biosimilar - Anti-PCSK9 mAb

Characteristics: Antibody Type: IgG1-kappa

Purification: Recombinant antibody expressed in mammalien cells and purified.

Isotype: IgG1 kappa

Application Details

Restrictions: For Research Use only

Handling

Buffer: PBS pH 7.5

Storage: -80 °C

Storage Comment: store at -80°C

Target Details for PCSK9 (Lodelcizumab Biosimilar)

Target: PCSK9 (Lodelcizumab Biosimilar)

Target Type: Biosimilar

Background: LGT209,NVP-LGT209
Ligelizumab (QGE031) is a humanized monoclonal antibody (mAb) designed for the treatment of severe asthma and chronic spontaneous urticaria.

CAS-No: 1355338-54-3